18 December 2020 - Camurus announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. 

This marks the first approval of a long-acting treatment for opioid dependence in Switzerland.

Read Camerus press release